Insulin Therapy for Postreperfusion Hyperglycemia

Summary

Glycemic control during liver transplantation is challenging especially after reperfusion of the liver graft. Insulin dose to treat postreperfusion hyperglycemia is retrospectively analyzed using historical data. The proposed dose then is prospectively applied to the patients to assess the adequacy of the insulin dose.

Eligibility

Inclusion Criteria:

* Liver recipients who showed hyperglycemia (blood glucose \>180mg/dL) after reperfusion of liver graft.

Exclusion Criteria:

* pediatric patients

Conditions3

Interventions1

Related trials

• Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes — Mostafa Bahaa
• Glycemic Variations During the Menstrual Cycle in Women With Type 1 Diabetes — Institut de Recherches Cliniques de Montreal
• Insulin Sensitivity After Breast Cancer — University of Copenhagen
• Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes — Nanjing Medical University
• DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes — Ohio State University
• FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS) — Sanofi
• Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes — Thomas Jefferson University
• Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2) — Thomas Jefferson University

Browse More Trials